Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected~* Certain specified laboratory values obtained within 30 days prior to study entry. More information on this criterion can be found in the study protocol.~* Documentation that pre-entry specimen for the primary immune activation endpoint responses has been obtained~* Female participants of reproductive potential must have a negative pregnancy test performed within 24 hours prior to study entry~* If engaging in sexual activity, female participants must use adequate forms of contraception while receiving study treatment and for 4 weeks after stopping the treatment. More information on this criterion can be found in the study protocol.~* Ability and willingness to provide informed consent~Additional Inclusion Criteria for Off-ART Participants:~* No antiretroviral therapy (ART) for at least 6 months prior to study entry and not likely to start within the 6 months after study entry~* CD4 cell count greater than or equal to 400 cells/mm3 at screening, obtained within 30 days prior to study entry~* For participants with previous ART use, documentation or recall of nadir CD4 cell count greater than or equal to 200 cells/mm3~* HIV-1 RNA viral load greater than or equal to 1,000 copies/mL obtained within 30 days prior to study entry~* No history of CDC category C AIDS-related opportunistic infections~* Karnofsky performance score greater than or equal to 70 within 30 days prior to study entry~Additional Inclusion Criteria for On-ART Participants:~* Receiving ART, defined as a regimen that includes three or more antiretroviral medications, for at least 24 months prior to study entry~* Required documentation that all HIV-1 viral loads (at least two) were below 400 copies/mL. More information on this criterion can be found in the study protocol.~* Screening HIV-1 RNA \<200 copies/mL within 30 days prior to study entry. More information on this criterion can be found in the study protocol.~* CD4 cell count \<350 cells/mm3 at screening, obtained within 30 days prior to study entry~Exclusion Criteria:~* Continuous use of certain specified medication for more than 3 days within 30 days prior to study entry. More information on this criterion can be found in the study protocol.~* Use of chloroquine or hydroxychloroquine within 3 months prior to study entry~* Known history of hypersensitivity to 4-aminoquinoline compounds (such as chloroquine or hydroxychloroquine)~* Active drug or alcohol use or dependence that, in the opinion of the investigator would interfere with adherence to study requirements~* Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry~* Renal insufficiency, defined as serum creatinine greater than 1.5 mg/dL, within 30 days prior to study entry~* History of retinal disease (i.e. confirmed retinopathy by ophthalmologic examination)~* History of neoplasm, within 5 years prior to study entry, other than treated in situ carcinoma or basal-cell or localized squamous cell carcinoma of the skin~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency at screening~* History of porphyria~* History of psoriasis~* History of cirrhosis~* History of seizure disorder~* History of tinnitus (ear and/or head noise lasting more than 5 minutes that occurs more often than once per week) or history of sudden hearing loss~* History of myopathy~* History of cardiac conduction abnormality or cardiomyopathy. More information on this criterion can be found in the study protocol.~Additional Exclusion Criteria for On-ART Participants:~- Plans to change ART regimen with the 6 months after study entry (change in ART regimen is only permitted if due to toxicity)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Chloroquine then Placebo for Off-ART Participants (Type: EXPERIMENTAL): Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
- B: Placebo then Chloroquine for Off-ART Participants (Type: EXPERIMENTAL): Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
- C: Chloroquine then Placebo for On-ART Participants (Type: EXPERIMENTAL): Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
- D: Placebo then Chloroquine for On-ART Participants (Type: EXPERIMENTAL): Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).